

# **Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026**

<https://marketpublishers.com/r/P11B96AD5F80EN.html>

Date: December 2025

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: P11B96AD5F80EN

## **Abstracts**

The Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry,

Forecast and outlook (2024-2031) Scope:

## Major Highlights

This report delivers a comprehensive overview of the Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement

and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### PREMATURE EJACULATION THERAPEUTICS PIPELINE INSIGHTS

- Premature ejaculation is a kind of sexual dysfunction that occurs when a man ejaculates sooner than expected by the partner during sexual intercourse.
- The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation.
- Treatment includes topical anesthetic creams and antidepressants. Therapeutic drugs, home remedies, and exercises are precise treatments for premature ejaculation.
- The overall premature ejaculation treatment market has attested the increased use of off-label drugs belonging to different drug classes such as selective serotonin reuptake inhibitors (SSRIs) like fluvoxamine, paroxetine, sertraline, and fluoxetine and PDE5 inhibitors like Cialis, Viagra, and Levitra. Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment.
- Pharmacological alteration of the ejaculatory response in patients with the condition is represented as a novel approach for the premature ejaculation treatment, and this will cause the steady replacement of psychosexual counseling which was previously regarded as the cornerstone of early ejaculation treatment.
- Also, the drugs in this class are known to exhibit high efficacy with minor side effects. The clinical pipeline of PE therapeutics is found to have few studies, and more percentage of reviews are exposed to in phase II stage of clinical trial development. CTC Bio is involved in the process of developing CDFR0812 as an adrenergic uptake inhibitor for the treatment of the disease. Ixchelsis Ltd. is developing IX-01 (oxytocin receptor antagonist). Ampio Pharmaceuticals entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Absorption Pharmaceuticals LLC in important collaboration with Kaiser Permanente has initiated clinical trials to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Prolong is a device from InnovaDerma that is an FDA approved device is used in the premature ejaculation treatment. Launches of devices are expected to restrain the growth of the global early ejaculation treatment market.
- For instance, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortin. Fortacin (topical spray) contains low doses of two anesthetics like lidocaine and prilocaine and is indicated for the treatment of premature ejaculation.
- A high strain of PE prevalence and associated chronic condition. The high-risk factor of occurrence is expected to be the key market driver for the premature ejaculation market in both developing and developed countries.

- Low effectiveness of non-pharmacological treatment and full accessibility to generic off-label drugs and OTC drugs are the prime factors that will boost market growth during the next decade.
- Likewise, pharmaceutical advances in PE drug formulation technology, the launch of premature ejaculation treatment awareness campaigns, insistence on the clinical advancement of love hormone receptor antagonists, and are known to be the latest trends that will positively impact the market.

## I would like to order

Product name: Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/P11B96AD5F80EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P11B96AD5F80EN.html>